Jubilant Pharmova's revenue rose 17.3% YoY to Rs 2,229 crore, broadly in line with expectations.
Set as Trusted Source
on Google Search
Jubilant Pharmova's revenue rose 17.3% YoY to Rs 2,229 crore, broadly in line with expectations.
While Pantaloons, TMRW and luxury businesses delivered double-digit growth in Q1, Systematix remains cautious on the pace of earnings recovery owing to margin pressure, input-cost inflation and continued investments in newer businesses.
Revenue rose 32% YoY and Ebitda surged 50% in Q1 FY27, but Systematix remains cautious on Lupin's near-term US business outlook amid increasing competition in key products.
Despite the target price hike, Systematix retained its Hold rating on Trent as it expects like-for-like growth to remain in the low-to-mid single digits amid ongoing store densification.
Vedanta Aluminium's successful ramp-up of Bharat Aluminium Company, Lanjigarh, Sijimali and captive coal mines as per guidance provides scope for further earnings improvement and a potential rerating, says Systematix.
Gulf Oil Lubricants India delivered a record operational performance in Q1 FY27, driven by exceptional volume growth and strong execution amid a challenging operating environment of sharp input cost inflation and supply disruptions.
UPL's Q1 revenue growth was supported by disciplined pricing actions, favorable currency movements and growth across segments, while profitability improved on the back of contribution margin expansion, better product mix and lower finance costs, adds the brokerage.
Divi's reiterated its confidence in sustaining double-digit revenue growth over the medium term, supported by commercialisation of validation projects, peptide opportunities, ongoing capacity additions and continued momentum in the custom synthesis business, adds Systematix.
The brokerage highlighted that Asian Paints' strong volume growth performance for a fourth straight quarter cements an upward shift in the trajectory; nevertheless, it factors in near-term volume growth at the lower end of the guided range in view of the base now turning high.
The brokerage said V-Mart's operational performance in the June quarter was broadly in line with expectations, with growth driven by healthy store additions, improving productivity and strong traction across both the V-Mart and Unlimited formats.
Coromandel's current valuation does not fully capture the long-term benefits of its capacity expansion, portfolio diversification and increasing share of value-added businesses, offering an attractive risk-reward opportunity for investors with a medium- to long-term investment horizon, believes the brokerage.
Systematix has lowered its FY27E/FY28E/FY29E earnings estimates for Infosys by 0.5%-1.8%, factoring in recent performance, cut in upper-end of guidance, higher competitive intensity across industry and client-specific issues.
Systematix maintaines its bullish view on Nuvoco Vistas Corporation and increased its target price, citing improved realisations, better cost efficiencies and strong execution of expansion projects.
Specialty Chemicals Q1 Preview: Although specialty sector valuations have been corrected from their post-Covid highs, fluorination-focused companies continue to trade at premiums to historical averages, adds Systematix
India's wind sector remains structurally positive, but Q1 FY27 capacity addition of 1.35GW, down 18% YoY and 15% QoQ, reflects a softer commissioning cycle and rising execution bottlenecks, adds the brokerage.
The brokerage believes that TCS is likely to minimise its revenue growth gap with peers in FY27E, supported by net-new large deals, and potential pick-up in developed markets.
The brokerage's cautious stance comes after Dr Reddy's disclosed that it had temporarily suspended commercial supplies of Semaglutide injections following the identification of an out-of-specification impurity during the API scale-up validation process
The brokerage expects domestic-focused pharma companies to outperform peers exposed to high-value US generic opportunities, with Sun Pharma, Cipla and Jubilant Pharmova emerging as its preferred picks ahead of Q1 FY27 results.
Systematix expects NIMs across its coverage universe to remain broadly stable or witness marginal sequential compression during Q1 FY27.
IT Sector Q1 Results Preview: Systematix has highlighted that tech companies are expected to report another quarter of muted growth despite seasonal strength, impacted by client-specific issues, weakness in select verticals and geopolitical uncertainty.